Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Enanta Pharmaceuticals (ENTA) Return on Invested Capital: 2018-2025

Historic Return on Invested Capital for Enanta Pharmaceuticals (ENTA) over the last 3 years, with Sep 2025 value amounting to -1.16%.

  • Enanta Pharmaceuticals' Return on Invested Capital fell 30.00% to -1.16% in Q3 2025 from the same period last year, while for Sep 2025 it was -1.16%, marking a year-over-year decrease of 30.00%. This contributed to the annual value of -0.86% for FY2025, which is 17.00% down from last year.
  • Latest data reveals that Enanta Pharmaceuticals reported Return on Invested Capital of -1.16% as of Q3 2025, which was down 6.09% from -1.09% recorded in Q2 2025.
  • Over the past 5 years, Enanta Pharmaceuticals' Return on Invested Capital peaked at -0.23% during Q3 2021, and registered a low of -1.16% during Q3 2025.
  • In the last 3 years, Enanta Pharmaceuticals' Return on Invested Capital had a median value of -0.90% in 2024 and averaged -0.89%.
  • Data for Enanta Pharmaceuticals' Return on Invested Capital shows a maximum YoY slumped of 33bps (in 2025) over the last 5 years.
  • Quarterly analysis of 5 years shows Enanta Pharmaceuticals' Return on Invested Capital stood at -0.30% in 2021, then declined by 10bps to -0.40% in 2022, then reached -0.45% in 2023, then reached -0.90% in 2024, then fell by 30bps to -1.16% in 2025.
  • Its Return on Invested Capital stands at -1.16% for Q3 2025, versus -1.09% for Q2 2025 and -0.97% for Q1 2025.